Integra LifeSciences (NASDAQ:IART) Stock Rating Raised to Hold at Truist Financial

Truist Financial upgraded shares of Integra LifeSciences (NASDAQ:IART) to a hold rating in a research note published on Thursday morning,Zacks reports.

Several other research analysts have also issued reports on the company. BMO Capital Markets began coverage on Integra LifeSciences in a research note on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price objective for the company. UBS Group initiated coverage on shares of Integra LifeSciences in a report on Tuesday, July 28th. They set a “neutral” rating and a $19.00 price target for the company. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Thursday, June 18th. Finally, Citigroup reaffirmed a “neutral” rating and set a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $18.86.

Integra LifeSciences Stock Performance

NASDAQ:IART opened at $16.09 on Thursday. The firm has a market capitalization of $1.25 billion, a PE ratio of -178.76, a price-to-earnings-growth ratio of 0.84 and a beta of 1.21. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. Integra LifeSciences has a 12-month low of $8.70 and a 12-month high of $20.49. The firm has a 50-day moving average price of $16.83 and a 200 day moving average price of $15.17.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The company had revenue of $418.76 million for the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Research analysts anticipate that Integra LifeSciences will post 2.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Hedge funds have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio bought a new position in shares of Integra LifeSciences in the second quarter worth about $82,000. Integrated Wealth Concepts LLC bought a new stake in shares of Integra LifeSciences during the second quarter valued at approximately $84,000. Sequoia Financial Advisors LLC increased its holdings in shares of Integra LifeSciences by 27.4% in the first quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company’s stock valued at $134,000 after purchasing an additional 3,059 shares in the last quarter. Amundi raised its position in Integra LifeSciences by 80.8% in the 1st quarter. Amundi now owns 19,430 shares of the life sciences company’s stock worth $183,000 after purchasing an additional 8,681 shares during the last quarter. Finally, State of Wyoming raised its position in Integra LifeSciences by 26.3% in the 4th quarter. State of Wyoming now owns 19,998 shares of the life sciences company’s stock worth $248,000 after purchasing an additional 4,168 shares during the last quarter. Institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.